Creation of the allergovaccines on the base of new technologies



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The achievements of molecular immunology and allergology at the last years allow to create new hypoallergenic and effective allergovaccines for ASIT. The structure of leading allergen epitopes responsible for cross-reactivity in allergic process was decoded. It was shown, that allergen cross-reactivity appears to be all-biological phenomenon that creates the certain difficulties in the development of AV specific preparations. Recombinant allergens play the important role in standardization of diagnostic and medical forms of allergens and allow to get comparable results on IgE-linking activities of natural and recombinant forms in the skin and in vitro-tests. Usage of new technologies in creation of AV for ASIT is perspective. Recombinant allergens define a new strategy in the development of allergen-specific therapy. The prospects of new technologies using the development of AV with high effectiveness in treatment of patients with allergic diseases, is justified and will allow to get the safe medical preparations, which action is directed on creation of antiallergic immune response.

About the authors

V N Fedoseeva

V N Fedoseeva

References

  1. Адо А.Д. Общая аллергология. М., «Медицина», 1978, с. 464.
  2. Johansson S.G. Hourinehane J.O. Bousquet A. et al. A revised nomenclature for Allergy. An EAACI position statement from the EAACI Nomenclature. Allergy, 2001, v. 56, p. 813-824.
  3. Allergen Nomenclature IUIS. ed Lowenstein H., 1/1X, 2004, Bull WHO, 2004, № 64, p. 767-770.
  4. Гущин И.С. Аллергия: аллергены, индукция и регуляция синтеза IgЕ. Патол. физиол. 1999, № 1, с. 24-28.
  5. Хутуева С.Х., Федосеева В.Н. Аллерген-специфическая иммунотерапия бронхиальной астмы. М., 2000, с. 124-139.
  6. Федосеева В.Н. Аэроаллергены. Materia medica, 1999, № 3, c. 26-39.
  7. Shmidt M., Hoffman D.R. Expression systems for production of recombinant allergens Intern. Archives of Allergy and Immunology. 2002, v. 128, p. 264-270.
  8. Eriksson N.E., Johnsson P. , Ryden B. Hypersensitivity to larvae of chironomids (non biting midges). Cross sensitization with crustaceans. Allergy, 1989, v. 44, p. 303-313.
  9. Ayuso R., Reese G., Leong-Kee S. et al. Molecular basis of arthropod cross-reactivity: IgE binding cross-reactive epitopes of shrimp, house dust mite and cockroach tropomyosins. Int. Arch. Allergy Immunol. 2002, v. 129, p. 38-48.
  10. Fernandes J., Reshef A., Patton L. et. al. Immunoglobulin E antibody reactivity to the major shrimp allergen tropomyosin, in unexposed Ortodox Jews. Clin. Exp. Allergy, 2003, v. 33, p. 956-961.
  11. Asturias J.A., Eraso E., Moneo I., Martinez A. Is tropomyosin an allergen in Anisakis? Allergy, 2000, v. 55 (9), p. 898.
  12. Leung P.S., Chow W.K., Duffey S. et. al. IgE reactivity against a cross-reactive allergen in crustacean and mollusca: evidence for tropomyosin as the common allergen. J. Allergy Clin. Immunol. 1996, v. 98, p. 954-961.
  13. Santos A.B.R., Chapman M.D., Aalberse R.C. et. al. Cockroach allergens and asthma in Brazil: Identification of tropomyosin as a major allergen with potential cross-reactivity with mite and shrimp allergens. J. Allergy Clin. Immunol. 1999, v. 104, p. 329-337.
  14. Федоскова Т.Г. Аллергия к «нежалящим» насекомым. (Распространенность, клиническая характеристика, специфическая диагностика и аллерген-специфическая иммунотерапия). Диссертация д-ра мед. наук. М., 2008, с.186-189
  15. Lowenstein H. Molecules for specific, causal treatment of type 1 allergy - today and tomorrow. Int. Rev. Clin. Immunol. 1995, v. 1, No. 2, p. 1-10.
  16. Asturias J.A., Gomes-Bayon N., Arilla M.C. et. al. Molecular characterization of American cockroach tropomyosin (Periplaneta Americana Allergen 7), a cross-reactive allergen. J. Immunol. 1999, v. 162, p. 4342-4348.
  17. Хаитов М.P. Рекомбинантные аллергены. Стратегия создания аллерговакцин нового поколения. Рос. Аллергол. Журн. 2004, № 1, с. 73-76.
  18. Хаитов Р.М., Федосеева В.Н., Федоскова Т.Г. и соавт. Тропомиозин и переклестно-аллергические реакции у больных с инсектной аллергией. Иммунология, 2006, № 3, с. 189-192.
  19. Aalberse R.C., Van Ree R. Crossreactive carbohydrate determinants. Clin. Rev. Allergy Immunol. 1997, v. 15, p. 375-387.
  20. Fotisch K., Altmann F., Haustein D., Vieths S. Involvement of carbohydrate epitopes in IgE-response of celery allergic patients. Int. Arch. Allergy Immunol. 1999, v. 120, p. 30-42.
  21. Jeong K.Y., Yum H.-Y., Lee I.-Y. et. al. Molecular cloning and characterization of tropomyosin, a major allergen of Chironomus kiiensis, a dominant species of nonbiting midge in Korea. Clin. Diagn. Lab. Immunol., 2004, v. 11, p. 320-324.
  22. Saarne T. , Kaiser R., Rasool O. et. al. Cloning and characterization of two IgE-binding proteins, homologous to tropomyosin and alpha-tubulin, from the mite Lepidoglyphus destructor. Int. Arch. Allergy Immunol. 2003, v. 130, p. 258-265.
  23. Wheeler W., Drachenberg K.J. New routes and formulations for allergen-specific immunotherapy. Allergy. 1997, v. 52, p. 602-612.
  24. Курбачева О.М. Аллерген-специфическая иммунотерапия. Рос. Аллергол. Журн., 2004, № 2, с. 47-54.
  25. Петрунов Б., Николаев Г., Константинова Д. Получение и характеристики химически модифицированного аллергена (аллергоида) из клещей Dermatophagoides рteronyssinus. Микробиол., эпидемиол. и иммунол., 1996, № 6, с. 53-54.
  26. Steven Smith С., Scott Smith А., Grier Т.,. Justus D E. Aluminum sulfate significantly reduces the skin test response to common allergens in sensitized patients. Clin. Mol. Allergy, 2006, vol.4, p.1.
  27. Petrov P.V., Khaitov R.M., Babakhin A.A. IgE-response to allergen polyelectrolyte complexes. Allergy and Clin. Immunol. News, 1992, v. 4, p. 87-91.
  28. Петров Р.В., Хаитов Р.М., Ильина Н.И. и соавт. Аллерготропины - препараты нового поколения для аллерген-специфической иммунотерапии. Рос. Аллергол. Журн., 2004, № 2, с. 13-19.
  29. Chapman M.D., Smith A.M., Vailes L.D. Pomes A. Recombinant Allergens for Immunotherapy. Allergy and Asthma Proceeding. 2002, v. 23, No. 1, p. 5-8 (4).
  30. Yasue M., Yokota T., Fukada M. et. al. Comparison of sensitization to crude and purified house dust mite allergens in inbred mice. Lab. Anim. Sci. 1998, v. 48, p. 346-352.
  31. Hakkart G.A., Aalberse R.C., Van Ree R. Epitope mapping of the house-dust-mite allergen Der p 2 by means of sitedirected mutagenesis. Allergy. 1998, v. 53, p. 165-172.
  32. Ibrahim A.S., Spellberg B.J., Avenissian V. et. al. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. 2005, v. 73 (2), p. 999-1005.
  33. Schein C.H., Jvanciuc O., Braun W.W. Bioinformatics Approaches to Classifying Allergens and Predicting Cross-Reactivity. Immunol. Allergy Clin. North Am. 2007, v. 27, v. 1, p. 1-27.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2009



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies